Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

Journal of Clinical Oncology

Volumn 25, Issue 33, 2007, Pages 5210-5217

  Thomas, Eva S ^a   Gomez, Henry L ^a   Li, Rubi K ^a   Chung, Hyun Cheol ^a   Fein, Luis E ^a   Chan, Valorie F ^a   Jassem, Jacek ^a   Pivot, Xavier B ^a   Klimovsky, Judith V ^a   De Mendoza, Fernando Hurtado ^a   Xu, Binghe ^a   Campone, Mario ^a   Lerzo, Guillermo L ^a   Peck, Ronald A ^a   Mukhopadhyay, Pralay ^a   Vahdat, Linda T ^a   Roché, Henri H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOXORUBICIN; EPIRUBICIN; IXABEPILONE; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DEOXYCYTIDINE; DISEASE PROGRESSION; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS;

EID: 36849071808     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.6557     Document Type: Article

References (25)

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150, 2006
2. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339:974-984, 1998
3. Valero V, Hortobagyi GN: Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 21:959-962, 2003
4. Bernard-Marty C, Cardoso F, Piccart MJ: Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9:617-632, 2004
5. Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol 205:275-292, 2005
6. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxelrefractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999
7. Fumoleau P, Largillier R, Clippe C, et al: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536-542, 2004
8. Lee FYF, Camuso A, Castenada S, et al: Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types. Proc Am Assoc Cancer Res 47:119, 2006 (abstr 503)
9. Wartmann M, Altmann KH: The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2:123-148, 2002
10. Perez EA, Lerzo G, Pivot X, et al: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414, 2007
11. Thomas E, Tabernero J, Fornier M, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399-3406, 2007
12. Low JA, Wedam SB, Lee JJ, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2734, 2005
13. Roché H, Yelle L, Peck R: Efficacy results of a phase II study of ixabepilone in patients with metastatic breast cancer previously treated with an anthracycline. Presented at the International Union Against Cancer World Cancer Congress, Washington, DC, July 8-12, 2006 (abstr 96-3). http://2006 .confex.com/uicc/uicc/techprogram/P8062.HTM
14. Lee FY, Camuso A, Castenada C, et al: Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 24:597s, 2006 (suppl; abstr 12017)
15. Bunnell CA, Klimovsky J, Thomas E: Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol 24:568s, 2006 (suppl; abstr 10511)
16. Yost KJ, Yount SE, Eton DT, et al: Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat 90:295-298, 2005
17. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
18. Albain KS, Nag S, Calderillo-Ruiz G, et al: Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 22:5s, 2004 (suppl; abstr 510)
19. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657, 2006
20. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005
21. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
22. Lee JJ, Swain SM: Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 24:1633-1642, 2006
23. O'Shaughnessy J, Blum J, Sandbach J, et al: Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004 (abstr 1070)
24. Seidman AD, Berry D, Cirrincione C, et al: CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized to T in HER2 normal MBC. J Clin Oncol 22:6s, 2004 (suppl; abstr 512)
25. Pignata S, De Placido S, Biamonte R, et al: Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian Cancer (MITO-4) retrospective study. BMC Cancer 6:5, 2006. http://www.biomedcentral .com/1471-2407/6/5